Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Deal counsel disclosed merger-of-equals structure with Biovail stockholders owning ~50.5% and Valeant stockholders ~49.5% post-close, plus a…
Sell-side framing of the merger highlighted Wellbutrin XL cashflow and Valeant's neurology assets, with deal completion viewed as highly likely; one Lazard…
C&EN characterized the $3.3B Biovail-Valeant tie-up as a stock-funded combination creating a specialty pharma with ~$1.75B in combined revenues centered on…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Valeant and Biovail entered merger-of-equals with Biovail acquiring Valeant. Valeant stockholders received $16.77/share special dividend + 1.7809 Biovail shares. Combined company renamed Valeant Pharmaceuticals International. Closed September 28, 2010.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Valeant Pharmaceuticals International, Inc. / Biovail Corporation (this deal) | 2010 | $3.3B | 18 |
| Valeant Pharmaceuticals International, Inc. / Dow Pharmaceutical Sciences, Inc. | 2009 | $285M | 66 |
| Valeant Pharmaceuticals International, Inc. / iNova Pharmaceuticals | 2011 | $700M | 63 |
| Valeant Pharmaceuticals International, Inc. / Xcel Pharmaceuticals, Inc. | 2005 | $280M | 42 |
| Valeant Pharmaceuticals International, Inc. / Dermik Laboratories (Sanofi dermatology unit) | 2011 | $425M | 36 |
| Valeant Pharmaceuticals International, Inc. / Bausch + Lomb | 2013 | $8.7B | 36 |
| Valeant Pharmaceuticals International, Inc. / Medicis Pharmaceutical Corporation | 2012 | $2.6B | 33 |
← Browse all deals · How we score deals
More: 2010 deals · Valeant Pharmaceuticals International, Inc. deals · Neurology deals